The Federal Circuit Court has instructed a Delaware federal judge to delay entering the final judgment in a case involving MSN Pharmaceuticals Inc. The litigation pertains to MSN’s efforts to launch a generic version of Novartis’s heart medication, Entresto. This judicial pause could impact the timeline for MSN’s market entry with its generic alternative, which, if approved, could potentially lead to significant shifts within the pharmaceutical market for heart medications.
For those interested in the specifics of this legal proceeding, more information is available in the detailed reporting by Law360. The related article can be accessed here.